ImmunityBio Faces Securities Class Action: Deadlines Approaching for Investors
ImmunityBio Faces Securities Class Action: A Call to Investors
As the world of finance and biotechnology intertwines, investors often find themselves navigating complex legal waters. A recent notice from Faruqi & Faruqi, LLP—a prominent national securities law firm—has brought attention to potential legal claims against ImmunityBio, Inc. (NASDAQ: IBRX). The firm is reminding investors of the impending deadline on May 26, 2026, for those who want to seek lead plaintiff status in a federal securities class action that has been initiated against the company.
The Legal Landscape
Faruqi & Faruqi is no newcomer to the realm of securities litigation. Established in 1995, the firm boasts a successful track record, having secured hundreds of millions of dollars for investors affected by corporate malpractice. The current investigation centers on allegations that ImmunityBio and its executives violated federal securities laws. Specifically, the firm claims that the company made false or misleading statements regarding its operations and business prospects, leading to investor losses.
A notable figure in this legal effort is Patrick Soon-Shiong, ImmunityBio's founder, who has been accused of significantly overstating the capabilities of Anktiva, a treatment involved in their trials. Such misrepresentation, according to the allegations, resulted in misleading statements about the company's business performance, thus harming investors' financial interests.
What Happened?
On January 23, 2026, ImmunityBio released updated Phase 2 clinical trial results for a chemotherapy-free immunotherapy regimen designed for patients battling glioblastoma. Despite high hopes, the press release stated that the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.